Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

146 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-04

Study Completion Date

2020-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SENTAD-COVID Study is an adaptive, prospective, multicentric, open-label, and randomized controlled clinical trial involving hospitalized adult patients with confirmed coronavirus disease 2019 (COVID-19) infection during the outbreak in Abu Dhabi, 2020. The patients were randomly allocated in a parallel assignment involving two groups of participants: Group A (Experimental arm): autologous non-hematopoietic peripheral blood stem cells (NHPBSC) therapy as add-on COVID-19 standard care, or Group B (No investigational intervention arm): COVID-19 standard care. Standard care is defined as per the "UAE National Guidelines for Clinical Management and Treatment of COVID-19". SENTAD-COVID Study was conducted in the Sheikh Khalifa Medical City (SKMC) of Abu Dhabi, as Primary Care Clinical Trial Unit, while the cell processing and investigational product formulation were completed by Abu Dhabi Stem Cells Center (ADSCC), according to Good Laboratory Practices (GLPs) and Good Manufacturing Practices (GMPs).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

NCT04532931

COVID-19

COMPLETED PHASE2

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

NCT04382586

COVID-19 Pulmonary Complications COVID-19

COMPLETED PHASE2

Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

NCT04805671

COVID-19

TERMINATED PHASE2/PHASE3

Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients

NCT04457609

COVID Pulmonary Infection Sars-CoV2

UNKNOWN PHASE1

Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19

NCT05365321

COVID-19 Mechanical Ventilation Complication COVID-19 Acute Respiratory Distress Syndrome

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Group A patients received autologous NHPBSC therapy through jet nebulization, in addition to the standard care, while Group B (No investigational intervention arm) received only the UAE approved standard care. The primary endpoints were the safety and efficacy assessment, measured as Adverse Reactions (ARs) incidence \[according to World Health Organization - Uppsala Monitoring Centre (WHO-UMC) causality assessment system\], rate of mortality within 28-days, and the time to clinical improvement of 2 points on a seven-category ordinal scale or discharge from the Hospital, whichever came first. Immune response profile, acute-phase serum markers, and coagulation testing profile were evaluated as well, before treatment (baseline - Day 0), at Day 14, and Day 21 (in patients with early response, defined as 2 points of difference in the clinical critical treatment index within 7 days of treatment, the assessment will be performed at Day 7). The trial was approved by the institutional ADSCC Research Ethics Committees (REC), and the Emirates Institutional Review Board (IRB) for COVID-19 Research and the written informed consent was obtained from all patients or from the patient's legal representative if the patient was too unwell to provide consent. SENTAD-COVID Study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice (GCP) Guidelines of the International Conference on Harmonization (ICH). The authors were responsible for designing the trial and for compiling and analyzing the data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Disease 2019 (COVID-19)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel assignment involving two groups of participants:

* Group A (Experimental arm): Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.
* Group B (No investigational intervention arm): COVID-19 standard care.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

None (open-label)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.

Group Type EXPERIMENTAL

Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)

Intervention Type BIOLOGICAL

SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.

Group B

COVID-19 Standard care.

Group Type ACTIVE_COMPARATOR

COVID-19 standard care

Intervention Type DRUG

UAE National Guidelines for Clinical Management and Treatment of COVID-19.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)

SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.

Intervention Type BIOLOGICAL

COVID-19 standard care

UAE National Guidelines for Clinical Management and Treatment of COVID-19.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UAECell19 Current COVID-19 standard care in the UAE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* RT-PCR Laboratory confirmation of COVID-19.
* Male or female aged ≥ 18 years.
* Interstitial lung change ≥ 3 judged by "Lungs Lobar based scoring" according to computed tomography (CT) scans.
* Hospitalized and symptomatic patients, referring one or more of the following symptoms (fever, cough, or shortness of breath), in association with (at least one): tiredness, runny nose, headache, sore throat, chills, muscle pain, or new loss of taste or smell).
* Ability to comply with test requirements and peripheral blood stem cells collection.
* The patient or legal representative agrees to participate in the study, and signs the SENTAD-COVID Study informed consent form.

Exclusion Criteria

* Pediatric patients (aged \< 18 years).
* Diagnosis of any kind of shock.
* Organ transplants in the past 3 months.
* Patients receiving immunosuppressive therapy.
* Diagnostic of Hepatitis B Virus (HBV) infection.
* Diagnostic of Human Immunodeficiency Virus (HIV) infection or Acquired Immunodeficiency Syndrome (AIDS).
* Current diagnosis of cancer.
* History of malignancies in the past 5 years.
* Pregnant or lactating women.
* Have participated in other clinical trials in the past 3 months.
* Inability to comply with test requirements and peripheral blood stem cells collection.
* Inability to provide informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No